A. Ør Knudsen

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.

M. Birrer, G. Lindahl, S. Hietanen, 2019, The Lancet. Oncology.

Trends in gynecologic cancer among elderly women in Denmark, 1980–2012

Ole Mogensen, O. Mogensen, J. Herrstedt, 2016, Acta oncologica.